PMID- 8391918
OWN - NLM
STAT- MEDLINE
DCOM- 19930810
LR  - 20181130
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 53
IP  - 14
DP  - 1993 Jul 15
TI  - Expression of mutated epidermal growth factor receptor by non-small cell lung 
      carcinomas.
PG  - 3217-20
AB  - The development of novel immunotherapy strategies for non-small cell lung cancer 
      (NSCLC) will be facilitated by the identification of tumor-specific targets. 
      Although the epidermal growth factor receptor (EGFR) is overexpressed in many 
      cases of NSCLC, its wide distribution in normal tissue may limit its suitability 
      as an immunotherapeutic target. However, mutations within the EGFR that are 
      unique to malignancies may provide specific targets for immunotherapeutic 
      intervention. For example, one mutant form, the type III deletion mutant of the 
      EGFR, that has been identified in glioblastomas contains a novel peptide sequence 
      in its extracellular domain which is detectable by anti-peptide antisera. In this 
      study, the prevalence of this type of mutation of the EGFR in NSCLC was 
      determined. Thirty-two frozen sections of primary NSCLC were examined by 
      immunocytochemistry to determine the presence of native and mutated EGFR. Native 
      EGFR was overexpressed in 12 of the 32 sections and a diffuse cellular 
      distribution of the EGFR type III deletion mutation was identified in five (16%) 
      of the specimens (2 of 13 squamous, 2 of 2 mixed, 0 of 10 adenocarcinoma, and 1 
      of 7 undifferentiated). This mutated EGFR was not detected in sections of normal 
      breast, lung, skin, ovary, colon, kidney, endometrium, and placenta. The type III 
      EGFR deletion mutant, expressed in some cases of NSCLC, may be a molecularly 
      defined, tumor-specific antigen in lung cancer.
FAU - Garcia de Palazzo, I E
AU  - Garcia de Palazzo IE
AD  - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, 
      Pennsylvania 19111.
FAU - Adams, G P
AU  - Adams GP
FAU - Sundareshan, P
AU  - Sundareshan P
FAU - Wong, A J
AU  - Wong AJ
FAU - Testa, J R
AU  - Testa JR
FAU - Bigner, D D
AU  - Bigner DD
FAU - Weiner, L M
AU  - Weiner LM
LA  - eng
GR  - CA06927/CA/NCI NIH HHS/United States
GR  - CA50633/CA/NCI NIH HHS/United States
GR  - CA51880/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
GS  - EGFR
MH  - Adenocarcinoma/chemistry
MH  - Amino Acid Sequence
MH  - Carcinoma, Non-Small-Cell Lung/*chemistry
MH  - Carcinoma, Squamous Cell/chemistry
MH  - ErbB Receptors/*analysis/genetics
MH  - Gene Deletion
MH  - Humans
MH  - Immunohistochemistry
MH  - Karyotyping
MH  - Lung Neoplasms/*chemistry
MH  - Molecular Sequence Data
MH  - *Mutation
EDAT- 1993/07/15 00:00
MHDA- 1993/07/15 00:01
CRDT- 1993/07/15 00:00
PHST- 1993/07/15 00:00 [pubmed]
PHST- 1993/07/15 00:01 [medline]
PHST- 1993/07/15 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1993 Jul 15;53(14):3217-20.